Abstract: The present invention addresses the problem of providing a composition with which a skin beautifying effect can be demonstrated even if collagen peptide intake is reduced. A composition that effectively demonstrates a skin beautifying effect, even with low-concentration collagen peptide, can be provided by making the weight ratio of collagen peptide, elastin peptide, and proteoglycan contained in the composition a prescribed ratio.

Abstract: It is intended to provide ACE inhibitory tripeptides which are not easily digested by digestive enzymes after being orally taken and thus have fewer tendencies to lose their ACE inhibitory activity in vivo. More specifically, 3 tripeptides having an ACE inhibitory activity and showing a hypotensive effect in an animal experiment are discovered from a thermolysin digestion product of sesame. These tripeptides respectively have amino acid sequences Leu-Ser-Ala, Val-Ile-Tyr and Leu-Val-Tyr and show an angiotensin converting enzyme inhibitory activity.

Abstract: It is intended to provide ACE inhibitory tripeptides which are not easily digested by digestive enzymes after being orally taken and thus have fewer tendencies to lose their ACE inhibitory activity in vivo. More specifically, 3 tripeptides having an ACE inhibitory activity and showing a hypotensive effect in an animal experiment are discovered from a thermolysin digestion product of sesame. These tripeptides respectively have amino acid sequences Leu-Ser-Ala, Val-Ile-Tyr and Leu-Val-Tyr and show an angiotensin converting enzyme inhibitory activity.

Abstract: It is intended to provide ACE inhibitory tripeptides which are not easily digested by digestive enzymes after being orally taken and thus have fewer tendencies to lose their ACE inhibitory activity in vivo. More specifically, 3 tripeptides having an ACE inhibitory activity and showing a hypotensive effect in an animal experiment are discovered from a thermolysin digestion product of sesame. These tripeptides respectively have amino acid sequences Leu-Ser-Ala, Val-Ile-Tyr and Leu-Val-Tyr and show an angiotensin converting enzyme inhibitory activity.

Abstract: The present invention provides a novel fat combustion accelerator which can promote lipid metabolism without changing the total consumption calories, characterized in that said fat combustion accelerator comprises proanthocyanidin as an active ingredient.

Abstract: The present invention provides an agent for improving physiological motor functions which is characterized in containing proanthocyanidin as an effective ingredient. It is useful as an agent for preventing and improving the fatigue in which rise in lactic cid value upon physical exercise is suppressed whereby muscular fatigue is reduced and continuous exercise is made easy, and particularly as an agent for prevention and improvement of muscular fatigue, and as a health food for prevention and improvement of fatigue.

Abstract: It is intended to provide ACE inhibitory tripeptides which are not easily digested by digestive enzymes after being orally taken and thus have fewer tendencies to lose their ACE inhibitory activity in vivo. More specifically, 3 tripeptides having an ACE inhibitory activity and showing a hypotensive effect in an animal experiment are discovered from a thermolysin digestion product of sesame. These tripeptides respectively have amino acid sequences Leu-Ser-Ala, Val-Ile-Tyr and Leu-Val-Tyr and show an angiotensin converting enzyme inhibitory activity.

Abstract: The present invention provides processes for preparing SDG (secoisolariciresinol diglycoside) known to be a precursor of compounds having female hormone-like activities such as enterolactone and enterodiol as well as foods and drinks that can be prepared by incorporating SDG and that are effective for various symptoms caused by imbalanced female hormones such as menopausal symptoms, osteoporosis, hyperlipidemia, hypertension, obesity, depression and hot flashes.

Abstract: By using xylobiose or xylooligosaccharide containing xylobiose as a main ingredient in place of lactulose, there is provided a blood ammonia lowering agent, a therapeutic agent of hyperammonemia or a therapeutic agent of hepatic encephalopathy that need be adminstered in smaller doses and which have no concern over side effects. Lactulose conventionally used as such drugs has to be administered in high doses and involves a safety problem when administered to patients with galactosemia or diabetes mellitus. The drug of the invention which contains xylobiose as a main ingredient solves these problems.